RC48
Phase 2Small molecule
RC48 is one of 57 small molecule programs targeting Disitamab Vedotin. It is currently in Phase 2.
4
Indications
7
Total Trials
6
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
193 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Avastin
RochePhase 3
Cyramza
Eli LillyPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Tuoyi
SSun Yat-sen University
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lynparza
AstraZenecaPhase 3
S-1
Taiho Oncology, Inc.Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer2 trials
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07474324·124 enrolled
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled
Treatment Failure2 trials
Second-line Treatment1 trial
Disitamab Vedotin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC48. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details